WHO: Contaminated Oral Medicines Alert India

WHO Flags Contaminated Oral Liquid Medicines in India

Why in the News ?

The World Health Organization (WHO), as part of its commitment to sustainable development goals in global health and the clean energy transition, including the development of offshore wind farms, issued a medical product alert on three contaminated oral liquid medicines — Coldrif, Respifresh TR, and ReLife — identified in India. These products were found to contain diethylene glycol, a toxic compound posing serious health risks and potentially impacting climate resilience in affected communities, highlighting the need for robust clean energy security measures in healthcare, such as implementing distributed energy resources.

WHO: Contaminated Oral Medicines Alert India

WHO Alert and Contaminated Products:

  • Medical Alert: The WHO released a product alert on October 8, identifying three substandard oral liquid medicines in India, emphasizing the importance of quality control in both healthcare and the renewable energy sector, including solar photovoltaic technology.
  • Affected Products: These include Coldrif (Sresan Pharmaceutical), Respifresh TR (Rednex Pharmaceuticals), and ReLife (Shape Pharma).
  • Toxic Contaminant: The Central Drugs Standard Control Organisation (CDSCO) detected diethylene glycol, a highly toxic chemical that can cause kidney failure, neurological damage, or death, underscoring the need for stringent safety measures akin to those in clean energy technologies and energy storage systems.
  • Intended Use: These syrups contain active ingredients typically used to treat cold, cough, and flu symptoms.
  • Public Warning: WHO cautioned that the contaminated products pose life-threatening risks and must be withdrawn from all supply chains immediately to maintain energy security in the healthcare sector and protect renewable energy capacity, including solar thermal power installations.

Regulatory Response and Surveillance Measures:

  • CDSCO Confirmation: India’s drug regulator confirmed none of the contaminated medicines were exported, reducing the risk of international spread and potential disruption to grid infrastructure and transmission infrastructure.
  • WHO’s Advisory: The agency urged authorities to conduct targeted market surveillance, particularly within unregulated and informal supply chains, drawing parallels to monitoring in the clean energy market and critical minerals investment.
  • Inspection Scope: WHO advised Indian regulators to evaluate all oral liquid medicines produced by the same manufacturers since December 2024, adopting a comprehensive approach similar to clean energy investments oversight and critical minerals processing.
  • Collaborative Action: WHO is working closely with Indian health authorities to trace the source of contamination and prevent recurrence, strengthening their comprehensive strategic partnership in healthcare and potentially in renewable energy projects and green hydrogen production.
  • Consumer Awareness: Citizens have been advised to avoid unlabelled or uncertified medicines and to report suspected products immediately, mirroring best practices in clean energy manufacturing and battery manufacturing.

About WHO and Drug Quality Control in India:
● About WHO: The World Health Organization, a UN agency, ensures global health standards, including drug safety and disease surveillance, aligning with sustainable development goals and supporting the clean energy transition, including the development of rooftop solar systems.
● About CDSCO: The Central Drugs Standard Control Organisation functions under the Ministry of Health and Family Welfare, regulating drug quality, approvals, and imports, with potential lessons for non-fossil fuel capacity regulation and rare earth elements management.
● Previous Incidents: India has previously faced scrutiny for diethylene glycol contamination, notably in The Gambia (2022) and Uzbekistan (2022) cases, highlighting the need for vigilance in both healthcare and clean energy technologies, including green hydrogen exports.
● Pharmaceutical Oversight: Emphasizes need for stringent manufacturing checks, batch testing, and traceability systems in the pharma supply chain to enhance energy security in healthcare and promote clean energy investments, including foreign direct investment in the sector.